Idexx Laboratories (IDXX) closed at $702.59 on November 11, 2026, up 0.9% from the previous close, on volume of 380,766 shares (30-day average 630,849).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 3, 2026 | Iron Condor or Double Vertical | 18-Dec-26460 P : 490 P : 600 C : 630 C | 720 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
Notable healthcare headlines for the week: Moderna, Pfizer, and CVS Health in focus
Seeking Alpha News (Sun, 8-Nov 9:05 AM ET)
IDEXX Laboratories Announces Third Quarter Results
Business Wire (Mon, 2-Nov 6:30 AM ET)
IDEXX Laboratories to Release 2026 Third Quarter Financial Results
Business Wire (Thu, 1-Oct 11:30 AM ET)
PRNewswire (Wed, 30-Sep 9:00 AM ET)
Business Wire (Thu, 17-Sep 3:00 AM ET)
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
Business Wire (Wed, 16-Sep 7:00 AM ET)
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
Business Wire (Mon, 31-Aug 2:00 PM ET)
IDEXX Laboratories Raises 2026 Guidance Amid Strong Diagnostic Revenue and Margin Expansion
Market Chameleon (Tue, 4-Aug 3:11 AM ET)
IDEXX Laboratories Delivers Double-Digit Revenue and EPS Growth, Boosts Outlook for 2025
Market Chameleon (Mon, 3-Nov 6:16 AM ET)
IDEXX Laboratories Lifts 2025 Outlook as Diagnostics Drive Double-Digit Growth
Market Chameleon (Mon, 3-Nov 2:37 AM ET)
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Idexx Laboratories trades on the NASDAQ stock market under the symbol IDXX.
As of November 12, 2026, IDXX stock price climbed to $705.05 with 130,582 million shares trading.
IDXX has a beta of 0.06, meaning it tends to be less sensitive to market movements. IDXX has a correlation of 0.00 to the broad based SPY ETF.
IDXX has a market cap of $55.54 billion. This is considered a Large Cap stock.
Last quarter Idexx Laboratories reported $1 billion in Revenue and $4.01 earnings per share. This beat revenue expectation by $22 million and exceeded earnings estimates by $.30.
In the last 3 years, IDXX traded as high as $769.98 and as low as $356.14.
The top ETF exchange traded funds that IDXX belongs to (by Net Assets): VTI, QQQ, VOO, VO, IVV.
IDXX has underperformed the market in the last year with a return of -1.0%, while SPY returned +12.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in IDXX shares. However, IDXX has outperformed the market in the last 3 month and 2 week periods, returning +20.2% and +25.3%, while SPY returned -0.9% and -1.4%, respectively. This indicates IDXX has been having a stronger performance recently.
IDXX support price is $687.37 and resistance is $717.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IDXX shares will trade within this expected range on the day.
